Table 1 Baseline characteristics of study participants with SAHE and without SAHE

Age (years)^a

58.9 ± 12.6

60.7 ± 13.7

58.7 ± 12.5

0.0505

Male^c

629 (67.6%)

76 (62.8%)

553 (68.3%)

0.2313

Ethnic Han^c

882 (94.7%)

111 (92.7%)

771 (95.2%)

0.2801

Current smoking^c

308 (33.1%)

38 (31.4%)

270 (33.3%)

0.0939

Current drinking^c

342 (36.7%)

44 (36.4%)

298 (36.8%)

0.5926

Hypertension^c

672 (72.3%)

80 (66.7%)

592 (73.1%)

0.1427

Diabetes mellitus^c

137 (14.7%)

18 (14.9%)

119 (14.7%)

0.9573

Dyslipidemia^c

91 (9.8%)

12 (9.9%)

79 (9.8%)

0.9547

Prior cerebral infarction^c

145 (7.4%)

19 (15.7%)

126 (15.6%)

0.9668

Prior antiplatelet use^c

157 (16.9%)

20 (16.5%)

137 (16.9%)

0.7229

Prior anticoagulant use^c

11 (1.2%)

2 (1.7%)

9 (1.1%)

0.8744

Admission SBP (mmHg)^a

168 ± 27

171 ± 29

167 ± 27

0.2417

Admission DBP (mmHg)^a

97 ± 18

96 ± 19

97 ± 18

0.4229

Admission GCS^b

14 (10–15)

10 (6–14)

14 (11–15)

< 0.0001

Admission NIHSS^b

10 (5–18)

17 (9–27)

10 (4–16)

< 0.0001

Admission CRP (mg/L)^b

5.6 (1.6–21.4)

15.1 (3.7–41.4)

5.0 (1.4–16.1)

0.0492

Admission WBC (10⁹/L)^b

8.8 (6.8–11.7)

11.3 (8.4–15.2)

8.5 (6.7–11.3)

< 0.0001

Location of hematoma^c

< 0.0001

 Lobar

252 (27.1%)

65 (53.7%)

187 (23.1%)

 Deep

679 (72.9%)

56 (46.3%)

623 (76.9%)

Intraventricular extension^c

325 (34.9%)

72 (59.5%)

253 (31.2%)

< 0.0001

Hematoma volume (ml)^b

15.8 (7.3–37.0)

46.3 (21.8–61.5)

13.9 (6.0–29.3)

< 0.0001

Surgical treatment^c

188 (20.2%)

39 (32.2%)

149 (18.4%)

0.0004